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Abstract Interleukin-18 binding protein is a novel glycoprotein
that we successfully cloned and expressed. First, murine
interleukin-18 binding protein was purified from the sera of
mice with endotoxin shock using ligand affinity chromatography.
The murine interleukin-18 binding protein cDNA was cloned
after RT-PCR using mixed primer pair sequences based on
partial murine interleukin-18 binding protein amino acid
sequence analysis. Subsequently, human interleukin-18 binding
protein cDNA was cloned from cDNA libraries of normal human
liver using murine interleukin-18 binding protein cDNA as a
probe. Next, we transiently expressed recombinant human and
murine interleukin-18 binding proteins in COS-1 cells and
purified them from culture supernatants. Both recombinant
interleukin-18 binding proteins did not exhibit species specificity
and prevented interleukin-18 binding to its receptor. In addition,
they inhibited interleukine-18 dependent IFN-Q production from
KG-1 cells effectively. These results suggest that the interleukin-
18 binding protein may possess interleukine-18 antagonist
activity.
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1. Introduction
Murine interleukin-18 (mIL-18) is a pleiotropic cytokine
consisting of 157 amino acids and was puri¢ed from murine
liver extracts in 1995 [1]. Human interleukin-18 (hIL-18) was
cloned from human liver cDNA libraries in 1996, using mIL-
18 cDNA as a probe [2]. The human interleukin-18 receptor
(hIL-18R/IL-1Rrp) was next puri¢ed and characterized in
1997 [3] and apparently, another IL-18 receptor subunit,
AcPL, has been cloned very recently [4].
Originally, mIL-18 was described as an interferon gamma
(IFN-Q)-inducing factor (IGIF), which was produced by liver
Kuppfer cells. The activity was identi¢ed in the sera of mice
with an endotoxin shock previously induced by injecting Pro-
prionibacterium acnes followed a week later by bacterial lipo-
polysaccharide [1,5]. Later, the cytokine was also found to be
produced by keratinocytes stimulated with a sensitizing agent
[6] and was also observed in the sera of humans with haema-
tologic malignancies [7] and autoimmune conditions such as
adult onset Still’s disease (AOSD) and rheumatoid arthritis
[8]. It was also reported that the excessive IL-18 production
may be involved in the pathogenesis of insulin dependent
diabetes mellitus (IDDM) in the NOD mouse model of the
disease [9] and that IL-18 augments Fas dependent natural
killer (NK) activity which may also result in autoimmune
reactions [10]. These lines of evidence suggested that the ex-
cessive production of IL-18 may be the cause of serious
chronic in£ammatory conditions or that it may exacerbate
disease states.
Therefore, we hypothesized that an IL-18 regulatory factor
might exist which neutralizes the e¡ects of an excessive and
potentially deleterious level of IL-18 in conditions where
IL-18 is implicated in disease. We attempted and succeeded
in detecting a murine IL-18 binding protein (mIL-18BP) from
the sera of mice su¡ering from endotoxin shock and which
contained an excessive level of IL-18 [5].
In this report, we describe the cloning and expression of the
cDNA for murine and human IL-18 binding proteins (mIL-
18BP and hIL-18BP) and demonstrate some of their biologic
properties.
2. Materials and methods
2.1. Cell culture and reagents
The L428 (human Hodgkin’s disease) cell line, which constitutively
expresses hIL-18R (hIL-1Rrp) [3] and the human myelomonocytic cell
line KG-1 were maintained at 37‡C with 5% CO2, in RPMI 1640
medium supplemented with 10% heat-inactivated fetal bovine serum
(FBS, BioWhittaker, Walkersville, MD, USA). COS-1 cells were also
maintained at 37‡C with 5% CO2, in Hybridoma-SFM medium (Gib-
co BRL, Grand Island, NY, USA).
The CHO-K1 (Chinese Hamster Ovary) cell line transfected with a
mIL-18R (mIL-1Rrp) expression vector plasmid was named CHO-
K1/mIL-18R and was maintained at 37‡C with 5% CO2, in Ham’s
F12 medium (Nissui, Tokyo, Japan) supplemented with 5% heat-in-
activated FBS. Recombinant human and murine [125I]IL-18s
([125I]hIL-18/[125I]mIL-18) were radioiodinated using the Bolton-
Hunter reagent (ICN, Costa Mesa, CA, USA) according to the manu-
facturer’s instructions [11]. Recombinant human IL-1L (R and D
System, Minneapolis, MN, USA) and [125I]hIL-1L (Amersham Phar-
macia Biotech., Uppsala, Sweden) were obtained commercially.
2.2. Puri¢cation of IL-18BP
The sera of mice su¡ering from endotoxin shock were prepared as
described previously [5]. These sera were applied to a Wheat Germ
Lectin (WGL) sepharose (Amersham Pharmacia Biotech.) column
equilibrated with PBS. After washing with PBS, the crude product
was eluted with PBS containing 0.5 M N-acetyl-D-glucosamine. Sev-
eral eluted fractions (OD at 280s 0.1) were pooled and dialyzed
against 20 mM PB, pH 7.2. The dialyzed material was then fractio-
nated on a DEAE-5PW (TOSOH, Tokyo, Japan) column with a
linear gradient from 0 to 0.5 M NaCl in 20 mM PB. The active
fractions were pooled and concentrated using an Ultrafree-15 centri-
fugal concentrator (Millipore, Bedford, MA, USA). The concentrate
was incubated for 2 h at 4‡C with biotinylated IL-18 which was
prepared from a mixture of rmIL-18 and NHS-Biotin (Bio-Rad, Her-
cules, CA, USA). In this step, mIL-18BP bound biotinylated IL-18 to
form a biotinyl-IL-18/IL-18BP complex. The complex was then intro-
duced into a streptavidin agarose (Calbiochem, San Diego, CA, USA)
a⁄nity column and eluted with 5 mM biotin in PBS. Eluted fractions
were analyzed by SDS-PAGE.
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2.3. N-terminal amino acid sequencing and peptide mapping
The puri¢ed IL-18/IL-18BP complex was electrophoresed on a 7.5^
15% gradient gel (Bio-Rad) and the gel was electroblotted onto a
PVDF membrane (Pro Blott, Applied Biosystems, Cambridge, UK)
for direct N-terminal amino acid sequencing according to the methods
of Matudaira et al. [12].
Another similarly electrophoresed gel was stained with CBB for
peptide mapping, which was performed by in gel digestion according
to the method of Hellman et al. [13], except that the enzymes used
were di¡erent (¢rst digestion: trypsin (Promega, Madison, WI, USA)
and second digestion: pepsin (Sigma, St. Louis, MI, USA)). The blot-
ted membrane and other peptides of interest obtained by in gel diges-
tion were analyzed by protein sequencer 473A (Applied Biosystems).
2.4. IL-18BP cDNA cloning using RT-PCR
Total RNA was isolated from the livers of CD-1 mice su¡ering
from endotoxin shock in accordance with the standard method [14].
The total RNA was reverse-transcribed using random hexamers and
ampli¢ed by PCR. The PCR was performed using mixed primer pairs
that were deduced from partial mIL-18BP amino acid sequences. The
sequences of the primers used were: sense primer: 5P-GCN-
GTNCCNACNAA-3P, antisense primer: 5P-GTYTTNARNCCRTC-
3P.
The partial mIL-18BP cDNA cloned by RT-PCR was subjected to
complete nucleotide sequencing using the 3P and 5P RACE system
(Gibco BRL). The gene-speci¢c sense primer sequences of the
3PRACE system were: gene-speci¢c sense primer: 5P-GATCCTGGA-
CAAGTGGCC-3P. The gene-speci¢c antisense primer sequences of
the 5PRACE system were: gene-speci¢c antisense primer 1: 5P-TG-
CAGGCAGTACAGGACAAGG-3P, gene-speci¢c antisense primer
2: 5P-GTGCTGGGTACTGCTTAGTTG-3P.
Both RACE systems were performed according to the manufactur-
er’s instructions. Similarly, hIL-18BP was cloned from the cDNA
libraries of normal human liver, using mIL-18BP cDNA as a probe.
All the nucleotide sequences for IL-18BP cDNA obtained were con-
¢rmed by the DNA sequencer 373A (Applied Biosystems).
2.5. Northern blot analysis
Northern blot analysis on various normal human tissues was per-
formed using human multiple Northern blot membrane (Clontech,
Palo Alto, CA, USA) according to the manufacturer’s instructions.
Partial fragments of the hIL-18BP and L-actin cDNA coding regions
were [32P]-labelled using a Ready To Go DNA labelling kit (-dCTP)
(Amersham Pharmacia Biotech.) and [K-32P]dCTP (Amersham Phar-
macia Biotech.) as a probe.
2.6. Expression and puri¢cation of recombinant human and murine
IL-18BPs
IL-18BPs cDNA with a 6xHis tag at the C-terminal end were sub-
cloned into the transient expression vector pcDNAI/Amp (Invitrogen,
Carlsbad, CA, USA) and the nucleotide sequences and correct align-
ments were con¢rmed by DNA sequencing. For the expression of
recombinant IL-18BPs (rIL-18BPs), the constructs were electropo-
rated into COS-1 cells and the transfectants that secreted rIL-18BPs
were cultured in serum-free hybridoma-SFM medium (Gibco BRL)
for 3 days. The supernatants were used for the puri¢cation of rIL-
18BP using Ni-NTA a⁄nity column chromatography (Qiagen, Chat-
worth, CA, USA).
2.7. [125I]IL-18 binding inhibition assay
L428 cells or CHO-K1/mIL-18R cells were suspended in binding
medium (RPMI 1640 medium containing 0.1% bovine serum albumin,
0.1% NaN3 and 100 mM HEPES, pH 7.2). The binding reactions
were performed on 3U106 L428 cells or 5U105 CHO-K1/mIL-18R
cells, respectively, for 1 h at 4‡C in 150 Wl of binding medium con-
taining various concentrations of IL-18BP and 1.0 nM [125I]IL-18 with
or without 500 nM unlabelled IL-18 as a competitor. After incuba-
tion, the reaction mixtures were layered over 200 Wl of phthalate oil
(dibutylphthalate:dioctylphthalate = 1:1), centrifuged at 6000Ug for
5 min at 15‡C and the radioactivity counts of the cell pellets, which
represent the amounts of cell-bound [125I]IL-18, were measured using
a gamma counter. The binding inhibition rate was calculated by the
following equation:
Binding inhibition rate %  T:B:C:3S:B:CT:B:C:3N:B:C:U100
Where, T.B.C.: total binding count (cpm), N.B.C.: non-speci¢c bind-
ing count (cpm), S.B.C.: sample binding count (cpm).
The T.B.C. was measured in the absence of IL-18BP and the
N.B.C. was obtained when the cold competitor was added to the
mixture.
2.8. Chemical cross-link
rhIL-18BP or rmIL-18BP were added to 8 Wl of PBS containing
1.0 nM [125I]hIL-18 or [125I]hIL-1L with or without 500 nM of unla-
belled competitive ligand, respectively, and incubated for 1 h at 4‡C.
After the addition of 1 Wl PBS containing 10 mg/ml bis(sulfosuccini-
midyl) suberate (BS3: Pierce, Rockford, ILL, USA), the mixtures
were incubated for 30 min on ice and the chemical cross-link reaction
was terminated with 1 Wl of 1 M Tris-HCl (pH 7.2). The reaction
mixtures were treated with 2.5% SDS, 10% glycerol and 2 mM
DTT and were electrophoresed on a 4^20% SDS-PAGE (Daiichi
Chemical, Tokyo, Japan) under reducing conditions. After electro-
phoresis, the gel was dried and exposed to a X-ray ¢lm for 2 days.
2.9. IL-18BP bioassay
The bioactivity of rIL-18BP was assessed by measuring the inhibi-
tion of the IFN-Q inducing activity of hIL-18 in KG-1 cells [18].
Brie£y, KG-1 cells were seeded at the concentration of 3U105/100
Wl/well in a 96 well microplate (Sumitomo Baklite, Tokyo, Japan).
The 100 Wl samples, which contain various concentrations of IL-
18BP and a constant concentration of hIL-18 (4 ng/ml), were added
to the wells and incubated at 37‡C for 24 h. RPMI 1640 medium
containing 10% FCS was used for the cell preparation and sample
dilutions. Then, IFN-Q activity induced in the culture supernatants
was assessed by ELISA.
3. Results and discussions
3.1. Puri¢cation of mIL-18BP
Primarily, we identi¢ed an activity in the sera of mice suf-
fering from endotoxin shock by a [125I]mIL-18 binding inhibi-
tion assay and revealed that the activity could be attributed
to a protein bound to mIL-18 by chemical cross-linking (data
not shown). We termed this protein mIL-18BP. The [125I]mIL-
18/mIL-18BP complex was observed to migrate as a 60^70
kDa broad band by chemical cross-linking, which suggested
the possibility that mIL-18BP was glycosylated (data not
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Fig. 1. Analysis of the puri¢ed mIL-18BP by SDS-PAGE. The
mIL-18BP puri¢ed by a streptavidin agarose column elution was
electrophoresed on a 7.5^15% gradient polyacrylamide gel under re-
ducing conditions. Subsequently, the gel was stained with CBB. The
molecular size is indicated on the left side of the ¢gure (in kDa).
The upper arrow shows the mIL-18BP and the lower arrow indi-
cates the biotinylated mIL-18, respectively.
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shown). Therefore, we employed WGL a⁄nity chromatogra-
phy for the partial puri¢cation of mIL-18BP. Separation of
sera on a WGL-Sepharose column resulted in a 100-fold pu-
ri¢cation as estimated by the binding inhibition assay (data
not shown). After concentrating mIL-18BP on a DEAE-5PW
column, biotinylated mIL-18 was added to the eluate to con-
struct a biotinyl-mIL-18/mIL-18BP complex. Further puri¢ca-
tion of this complex was performed by streptavidin agarose
column chromatography and the puri¢ed sample was revealed
to produce two major bands, corresponding to biotinylated
mIL-18 (20 kDa) and mIL-18BP (40 kDa^55 kDa) by SDS-
PAGE (Fig. 1). These results suggested that the puri¢ed mIL-
18BP (40 kDa^55 kDa) was the same protein that was de-
tected in the murine sera by chemical cross-linking.
3.2. Nucleotide and deduced amino acid sequences of human
and murine IL-18BPs
Using RT-PCR cloning, we obtained complete cDNA se-
quences for human and murine IL-18BPs, which were 585 bp
and 582 bp in size, respectively. (DDBJ/EMBL/GenBank nu-
cleotide database, accession numbers: AB019504 (for hIL-
18BP) and AB019505 (for mIL-18BP)).
According to the amino acid sequences deduced from their
cDNAs, hIL-18BP consists of 164 amino acids with a
30 amino acid signal peptide and four potential N-glycosilated
sites and, correspondingly, mIL-18BP consists of 165 amino
acids with a 28 amino acid signal peptide and four potential
N-glycosilated sites. There is 60.8% homology between the
human and murine IL-18BP amino acid sequences (Fig. 2).
From a hydrophilisity/hydrophobicity plot of IL-18BP, IL-
18BP is predicted not to have a transmembrane region.
3.3. Properties of human and murine IL-18BPs
We performed Northern blot analysis using a partial frag-
ment of a hIL-18BP cDNA coding region as a probe. Among
the normal human tissues examined, hIL-18BP mRNA was
expressed strongly in the heart, lung and placenta, and ap-
peared as a 1.6 kb single band (Fig. 3). According to the data
reported previously, hIL-18 mRNA is strongly expressed in
skeletal muscle, kidney and pancreas [2] and hIL-18R (hIL-
1Rrp) mRNA is expressed strongly in the lung and liver [3].
The mRNAs for these three factors have di¡erent expression
patterns and we could not ¢nd a clear correlation between
these patterns.
Next, using rhIL-18BP and rmIL-18BP, a chemical cross-
linking reaction was performed with [125I]hIL-18. The results
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Fig. 3. RNA blot analysis of hIL-18BP mRNA expression. North-
ern blot analysis of hIL-18BP mRNA in normal human heart,
brain, placenta, lung, liver, skeletal muscle, kidney and pancreas
was performed using hIL-18BP cDNA as a probe (A). L-Actin was
analized similarly for standardization of the blot (B). Each lane con-
tains 2 Wg of poly(A)RNA. The molecular size is indicated on the
left side of the ¢gure (in kb). The arrow shows the hIL-18BP
mRNA and the arrow head indicates L-actin mRNA, respectively.
Fig. 2. Deduced amino acid sequences of human and murine IL-18BPs. The alignment of amino acid sequences for human and murine
IL-18BPs and their homology are shown. Identical amino acid residues are indicated by asterisks (*). Homologous amino acid residues are indi-
cated by periods (.). The N-terminal amino acid sites for human and murine IL-18BPs are indicated by vertical arrows. Potential N-glycosyl-
ated binding sites are shown in bold characters. Partial amino acid sequences of human and murine IL-18BPs, we puri¢ed from human urine
and the sera of mice, respectively, are shown underlined.
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showed that rhIL-18BP and rmIL-18BP singly bound to hIL-
18 and mIL-18, respectively, and bound to their inverse lig-
ands and an excess of cold hIL-1L, which was the ligand
structurally similar to hIL-18, could not prevent hIL-18BP
binding to [125I]hIL-18 (Fig. 4). Similarly, by another chemical
cross-linking, we revealed that rIL-18BPs could not bind to
[125I]hIL-1L (data not shown).
Furthermore, we also performed a [125I]IL-18 binding in-
hibition assay and measurement of the IL-18 neutralizing ef-
fect of rIL-18BP using KG-1 cells. The results suggested that
rIL-18BP dose dependently prevented the binding of the lig-
ands to their respective receptors (Fig. 5) and inhibited the
activity of IL-18 as an inducer of IFN-Q in KG-1 cells (Fig. 6).
Therefore, IL-18BP may function as an IL-18 antagonist.
These results indicate that IL-18BP may be expected to have
the similar function as an anti-IL-18 antibody reported to
inhibit IL-18 activity [1,15].
Recently, Novik D. et al. reported on the isolation and
puri¢cation of a soluble IL-18 receptor present in human
urine [16,17]. This soluble human IL-18R was found to be a
38 kDa protein that did not exhibit species speci¢city. Corre-
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Fig. 6. The hIL-18 neutralizing e¡ect of rIL-18BPs with the assay
of IFN-Q production on hIL-18 in KG-1 cells. The Y axis represents
the amount of IFN-Q induced from KG-1 cells. The X axis repre-
sents the concentrations of rhIL-18BP (A) and rmIL-18BP (B). The
closed column denotes the amount of IFN-Q from KG-1 cells with-
out rIL-18BP. Each value is presented as a mean þ S.D. (n = 3).
Fig. 5. Binding inhibition activity of rhIL-18BP on IL-18 binding to
L428 cells or CHO-K1/mIL-18BP cells. The binding inhibition assay
on L428 cells or CHO-K1/mIL-18R cells was performed to estimate
the ability of rhIL-18BP to prevent IL-18 binding to its receptor.
The Y axis represents the binding inhibition rate as described under
Section 2. The X axis represents the concentration of rhIL-18BP
employed. The open column denotes the result with L428 cells and
the hatched column denotes the result with CHO-K1/mIL-18R cells.
Each value is presented as a mean þ S.D. (n = 3).
Fig. 4. Analysis of the binding abilities of rIL-18BPs with [125I]hIL-
18 by chemical cross-linking. rhIL-18BP or rmIL-18BP were incu-
bated with 1.0 nM of [125I]hIL-18 in the presence or absence of a
500-fold molar excess of unlabelled hIL-18, mIL-18 or hIL-1L.
Chemical cross-linking reactions and electrophoresis were performed
as described under Section 2. Subsequently, the gel was subjected to
autoradiography. The molecular size is indicated on the left side of
the ¢gure (in kDa). The arrow shows the position of the hIL-18/
rhIL-18BP and hIL-18/rmIL-18BP complexes.
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spondingly to this, we also puri¢ed a similar protein from
healthy human donor urine by the above mentioned puri¢ca-
tion methods. By amino acid sequencing, we revealed that the
puri¢ed protein was the same one as the hIL-18BP we have
cloned in this report (Fig. 2). There is a possibility that the
soluble IL-18R described by Novik is the same protein as the
hIL-18BP we have cloned. However, we could not ¢nd any
evidence that hIL-18BP had a transmembrane region and we
therefore have the opinion that IL-18BP is not a soluble form
of the IL-18 receptor currently.
Thus, we have clari¢ed some biologic properties of IL-
18BP, but others remain to be revealed. For example, if any
correlation exists between IL-18BP expression and diseases as
well as a comparison of the IL-18 binding a⁄nities between
anti-IL-18 antibody and IL-18BP. Some of these studies are
now being performed and revealing these properties will be-
come our future works.
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